Active substance

Results for the substance talazoparib

5 results

About this active substance

Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor used in the treatment of metastatic or locally advanced breast cancer associated with BRCA mutations. It works by inhibiting DNA repair in tumor cells, leading to their death.

The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and undergo regular medical check-ups to monitor the response to treatment.

Patients should be aware of potential side effects, such as fatigue, nausea, or a decrease in blood cell counts. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, nausea, anemia, and a decrease in platelet counts. In rare cases, severe reactions such as myelosuppression or tumor lysis syndrome may occur. Patients should be informed of these risks before starting treatment.